We say we care about mental health in America

We say we care about mental health in America.
But the data—and my front-line experience—say otherwise.

We are overmedicating, underfunding, and pathologizing poverty, trauma, and stress.
Instead of addressing why people are sick, we throw pills at symptoms.

🧠 In my latest article for Psychiatric Times, I make the case that we’ve built a system that profits off disease—not health.
We’re not solving the problem. We’re institutionalizing it.

If we want to make America healthy again, we need to stop doing the wrong things.

👉 Read the full piece here: https://www.psychiatrictimes.com/view/if-we-want-to-make-america-healthy-again-we-are-doing-the-wrong-thing

🧠 Blog Post: The Dark Mirror—How Screen Time Drains Our Mental Health

It’s no secret that screen time affects our mental health—but we still underestimate just how deeply it cuts.

As a psychiatrist, I find myself glued to my phone far more than I’d like. I’m not scrolling TikTok—I’m answering emails, responding to messages, and compulsively checking patient updates. Yet, even in this “productive” digital use, I feel drained. The compulsion to keep checking leaves me feeling hollow and anxious.

Now imagine that same digital pull in the hands of a developing mind.

A recent study in JAMA examined over 4285 adolescents and found a clear link: teens with high levels of addictive digital media use were significantly more likely to report depression, anxiety, and suicidal thoughts.

The connection isn’t surprising. Much of what’s consumed online isn’t educational or uplifting—it’s filtered perfection, highlight reels, and influencer fantasy. The more time spent scrolling, the easier it is to feel like you’re falling behind in life, socially or emotionally.

It’s telling that Steve Jobs famously limited his own children’s access to screens, despite pioneering the very technology we now feel chained to.

This isn’t about demonizing devices—it’s about reclaiming our attention and protecting mental space, especially for young people.

We need digital hygiene just like we need physical hygiene. That means:

  • Setting screen-time boundaries
  • Promoting offline connection
  • Reframing how we compare ourselves to curated content

Mental health isn’t just shaped in the therapy room—it’s shaped by the world we scroll through every day.

Understanding Psychiatry: Science vs. Skepticism

🧠 “Psychiatry is a scam.” “Big Pharma controls your brain.” “Mental illness isn’t real.”

You’ve heard the takes. Now here’s the truth.

In my new article for Psychiatric Times, I dive headfirst into the controversy:
👉 Understanding Psychiatry: Navigating Skepticism and Science
https://www.psychiatrictimes.com/view/understanding-psychiatry-navigating-skepticism-and-science

I don’t dodge the hard questions—about overmedication, broken trust, and bad science—but I also push back against lazy anti-psychiatry takes that ignore the very real suffering of patients.

If you care about the future of mental health care, this one’s worth your time.

Mirtazapine: A unique tool in the antidepressant toolbox

Mirtazapine isn’t your typical SSRI—and that’s exactly why it can be useful in the right context.

✅ When to consider mirtazapine:

  • Depression with insomnia
  • Poor appetite or weight loss
  • Concern about sexual side effects
  • Patients struggling with GI intolerance to SSRIs

⚠️ When to avoid it:

  • Obesity or metabolic syndrome
  • Risk of daytime sedation
  • Orthostatic hypotension history

Mechanistically, it’s a noradrenergic and specific serotonergic antidepressant (NaSSA). It works via alpha-2 autoreceptor blockade, enhancing 5-HT1A transmission while avoiding 5-HT2/3 activity—translating to fewer GI and sexual side effects.

💡 Pro tip:
Sedation is dose-dependent and paradoxical:
Lower doses (7.5–15 mg) = more sedation
Higher doses (30–45 mg) = less sedation

In short, mirtazapine shines in cases where sleep, appetite, or tolerability limit other antidepressants—but use it strategically.

Reject dogma—embrace nuance in Psychiatry

🔹 Psychoanalysis should not be treated as sacred doctrine. Freud was a clever and influential thinker, but not a prophet.


🔹 Biological psychiatry is equally vulnerable to dogma. Not every symptom signals a disease, and not every distress warrants medication.


🔹 That said, evidence-based pharmacology has its place—especially when medications show clear, replicable benefits in defined clinical conditions.

The future of psychiatry lies in balanced thinking, not blind allegiance—to Freud, to biology, or to any single model of mind.

Understanding Social Anxiety Disorder: Key Insights and Treatments

What if your biggest fear was simply being seen?
For millions living with Social Anxiety Disorder (SAD), everyday interactions—like answering a question in class or speaking up at work—can feel terrifying. Despite being one of the most prevalent and impairing anxiety conditions, SAD remains widely under-recognized.

📊 Up to 8.4% of people meet criteria for SAD in a given year, yet only 20–40% recover after 20 years without treatment (Ruscio et al., 2008). Median age of onset? Just 13 years old.

👤 Case Vignette: When Fear Takes Over

At 15, “Jenna” stopped raising her hand in class—not because she didn’t know the answers, but because she was terrified of being laughed at. By college, she avoided presentations, skipped networking events, and turned down internships. Her friends thought she was shy. One professor suggested depression. But underneath was a paralyzing fear of judgment: classic Social Anxiety Disorder.

🤝 What Is Social Anxiety Disorder?

SAD is more than introversion or shyness. It’s a persistent, intense fear of being judged, embarrassed, or negatively evaluated in social or performance situations. This fear leads to avoidance behaviors that impair social, academic, and occupational functioning.

⚠️ Why Is It So Often Missed?

SAD is frequently overshadowed by overlapping symptoms seen in:

  • Major Depressive Disorder (social withdrawal, low self-esteem)
  • Generalized Anxiety Disorder (excessive worry)
  • Avoidant Personality Disorder (longstanding social inhibition)
  • Body Dysmorphic Disorder (fear of negative evaluation tied to appearance)

Because of this diagnostic overlap, many individuals go undiagnosed—or misdiagnosed—for years.

🧠 Clinical Considerations

1. SAD Is Not “Just Shyness”

Shyness is a personality trait; SAD is a clinical condition. The difference lies in impairment: SAD interferes with daily life, relationships, academic goals, and career opportunities.

2. Early Onset, Long Course

Most individuals report symptoms starting in early adolescence. Without intervention, SAD often persists into adulthood and increases the risk of depressionsubstance use, and functional disability.

3. Functional Impairment Is Significant

SAD can lead to:

  • Academic underachievement
  • Avoidance of job interviews or public speaking
  • Social isolation
  • Delayed life milestones (e.g., dating, career advancement)

4. Evidence-Based Treatments Exist

🧠 Cognitive Behavioral Therapy (CBT):

  • Gold-standard psychotherapy
  • Targets negative thought patterns and avoidance behaviors
  • Often includes exposure exercises to feared situations
  • Group CBT is especially effective for SAD

💊 Pharmacologic Options:

  • First-line: SSRIs (e.g., sertraline, paroxetine)
  • SNRIs: Like venlafaxine, also effective
  • Beta-blockers: May help with performance-only SAD (e.g., public speaking)
  • BenzodiazepinesNot recommended due to dependence risks and avoidance reinforcement

🔄 Combined Therapy

Some individuals benefit most from CBT + medication, particularly those with moderate-to-severe or treatment-resistant symptoms.

📣 Call to Action

Too many individuals live in silence with Social Anxiety Disorder. If you or someone you know avoids social situations due to fear of judgment, don’t ignore it. SAD is real. It’s common. And—most importantly—it’s treatable.

👉 Talk to a mental health professional
👉 Share this post to raise awareness
👉 Start the conversation

📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

📉 Overdose Deaths in the U.S. Dropped Nearly 27% in 2024 – A Sign of Hope 🇺🇸

According to newly released CDC data, the U.S. experienced a nearly 27% decline in overdose deaths last year — the first major drop in over five years. While the crisis is far from over, this marks a critical turning point and a reason for cautious optimism.

Key contributors to this progress include:

✅ Expansion of harm reduction strategies

✅ Increased access to naloxone and medications for opioid use disorder

✅ Shifts in drug supply dynamics and targeted public health interventions

As someone on the front lines caring for patients every day, I’ve witnessed firsthand the devastating toll of opioid addiction. I’ve lost patients to this crisis — and I’ve also seen close friends and family fight their way back from the brink. Their recovery wouldn’t have been possible without access to critical resources, especially life-saving medications and sustained support.

This progress didn’t happen by chance — it’s the result of continued investment in prevention, treatment, and recovery. We cannot afford to lose momentum now. If anything, this is the moment to double down.

Let’s keep the pressure on. Reach out to your representatives. Push for increased funding. Our collective commitment has brought us this far — now let’s go even further. Lives depend on it.

Let’s build on this progress with compassion, science, and unwavering commitment.

Avoid Tianeptine: FDA Alerts Consumers to Risks

The U.S. Food and Drug Administration (FDA) has issued a critical health warning about the growing availability of tianeptine, a dangerous, unapproved substance being sold as a dietary supplement under names like Zaza, Tianna Red, Pegasus, and others.

Commonly referred to as “gas station heroin”, tianeptine mimics opioid-like effects and is being sold in convenience stores, gas stations, smoke shops, and online—posing serious health risks to the public.

⚠️ Why This Matters:

Tianeptine is not approved for any medical use in the U.S. Despite this, it is widely marketed for supposed benefits like mood enhancement, anxiety relief, or cognitive boost. These claims are not supported by clinical evidence, and the risks are significant.

🩺 Serious Health Risks Associated With Tianeptine:

⚠️ Death, particularly when combined with alcohol or other substances

⚠️ Respiratory depression (slow or stopped breathing)

⚠️ Seizures

⚠️ Loss of consciousness

⚠️ Confusion and agitation

⚠️ Opioid-like withdrawal symptoms

🛑 What You Can Do:

Report adverse reactions to the FDA via MedWatch: https://www.fda.gov/medwatch

Avoid any products labeled as containing tianeptine.

Do not trust unregulated supplements marketed for mental clarity or energy.

📌 Quick Summary:

  • Tianeptine = dangerous, unapproved opioid-like drug
  • Sold as a supplement under names like Zaza or Tianna Red
  • Linked to seizures, coma, and death
  • Avoid these products and warn others
  • Report side effects to the FDA MedWatch Program

The Importance of Distinguishing Suicidal Behaviors

This is the subject of a recent discussion I had with a colleague regarding the differences between a suicide attempt and a suicide gesture. Though these terms are sometimes used interchangeably in casual conversation or even in clinical documentation, they carry fundamentally different meanings—both in terms of patient risk and in how we, as clinicians, should respond.

Our conversation emerged from a case involving a patient with borderline personality disorder who presented to the emergency department after ingesting a small quantity of over-the-counter medication. The intent was unclear. Was this a serious attempt to end her life? Or was it a gesture—an act of desperation without the intention to die, but rather to communicate emotional distress?

The question is not academic. Our interpretation of the event determines our risk formulation, our documentation, our treatment planning, and even how we communicate with the patient and their support system. Yet, it is precisely in these gray areas that clinicians often struggle, and where outdated or stigmatizing language can do real harm.

Defining the Terms: Clinical and Functional Differences

suicide attempt refers to an act of self-harm with at least some intent to die. The degree of lethality may vary, but what distinguishes an attempt is that the individual believed the act could result in death and engaged in it with that goal in mind—even if ambivalence was present. The National Institute of Mental Health (NIMH) and the Columbia-Suicide Severity Rating Scale (C-SSRS) define this with some specificity: any potentially self-injurious behavior with non-zerointent to die, regardless of outcome.

In contrast, a suicidal gesture is a behavior that mimics suicidal behavior or appears life-threatening but is typically not intended to be fatal. The function is often communicative or affect-regulating rather than aimed at death. Classic examples include superficial wrist-cutting, ingesting a sub-lethal dose of medication, or tying a noose but not tightening it. These acts often occur in interpersonal contexts and can be seen as efforts to signal pain, elicit help, or assert control in the face of perceived abandonment.

Why the Distinction Matters

It might be tempting to dismiss suicidal gestures as “attention-seeking” or “manipulative,” but this framing is both clinically dangerous and ethically fraught. Individuals who engage in gestures often experience intense psychological suffering, and repeated gestures are a well-established risk factor for future suicide attempts and completed suicide.

From a risk assessment standpoint, gestures should be taken seriously, especially when they become part of a pattern. While the intent to die may not be present in a given gesture, intent can shift quickly, particularly in individuals with mood disorders, personality pathology, or under the influence of substances.

From a treatment perspective, understanding the function of the behavior—whether it is to relieve affective tension, to communicate distress, or to punish oneself—is crucial to tailoring interventions. For instance, dialectical behavior therapy (DBT) explicitly targets self-harm and suicidal gestures as part of its hierarchy of treatment priorities, recognizing the urgency and potential danger of these behaviors even when lethality is low.

Conclusion: Clarify, Don’t Categorize

Ultimately, the conversation with my colleague reminded me that the real clinical challenge is not to label a behavior as a suicide attempt or a gesture, but to understand its meaning in the life of the patient. Both require empathy, structure, and a willingness to engage with complexity. Whether a patient wants to die or wants their suffering to be seen and acknowledged, both deserve serious clinical attention.

By sharpening our definitions and approaching these behaviors with nuance, we can better serve patients in crisis and avoid the pitfalls of assumptions—especially in emotionally charged clinical environments like emergency rooms, inpatient units, or high-acuity outpatient settings.

EMA Warns of Suicidal Ideation from Finasteride

In a significant update to its safety guidance, the European Medicines Agency (EMA) has officially recognized suicidal ideation as a potential side effect of finasteride. The EMA is urging healthcare professionals to advise patients to stop treatment and seek medical help if they experience depressed mood, depression, or suicidal thoughts while taking the drug.

This decision follows a growing number of reports linking finasteride, particularly in younger men using it for androgenic alopecia (male pattern baldness), to neuropsychiatric side effects. While previous warnings have addressed sexual dysfunction, this marks a critical shift in regulatory focus to mental health.

💊 What Is Finasteride?

Finasteride is a 5α-reductase inhibitor used to treat:

  • Benign prostatic hyperplasia (BPH) in a 5 mg daily dose (Proscar)
  • Male pattern baldness (androgenic alopecia) in a 1 mg daily dose (Propecia)

It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT)—a potent androgen implicated in hair loss and prostate growth.

⚠️ The EMA’s Updated Warning

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed post-marketing surveillance data and published literature and concluded that:

“There is sufficient evidence to support a causal relationship between finasteride and the risk of suicidal ideation.”

Key recommendations:

  • Suicidal ideation will be added to the drug’s product information as a potential adverse effect.
  • Healthcare professionals should proactively inform patients about this risk.
  • Patients should be advised to discontinue treatment immediately and seek medical advice if they experience changes in mood or mental health.

🧠 Possible Mechanisms Behind Finasteride’s Psychiatric Effects

The exact mechanisms linking finasteride to depression and suicidality remain unclear, but several biological hypotheseshave been proposed:

1. Neurosteroid Depletion

Finasteride inhibits 5α-reductase, which not only converts testosterone to DHT but also helps produce neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC).

  • These neurosteroids have potent GABAergic activity, contributing to anxiolytic and antidepressant effects.
  • Inhibition leads to decreased GABA-A receptor modulation, potentially increasing anxiety, depression, and suicidal thoughts.

2. Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation

Altered steroid metabolism may dysregulate the HPA axis, increasing cortisol levels, a well-known biomarker of depression and suicidal behavior.

3. Persistent Epigenetic Changes

Some animal and human data suggest that finasteride may induce long-lasting changes in gene expression related to stress response and mood regulation, even after discontinuation—supporting the idea of post-finasteride syndrome (PFS).

4. Neuroinflammation

Reduced neurosteroids may increase neuroinflammatory signaling, a growing area of interest in the neurobiology of depression and suicidality.

🧾 Final Thoughts

The EMA’s announcement is a sobering reminder that drugs affecting hormonal pathways can have wide-reaching systemic effects, including on the brain. With better awareness, screening, and patient education, we can minimize harm and support individuals who may be at risk.

Powered by WordPress.com.

Up ↑